Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 4/20 | 0.59 |
| ▸ | PDGFRA | P16234 | 4/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | ABCG2 | Q9UNQ0 | 6/20 | 0.53 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.53 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.52 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.52 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.52 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | IGF1R | P08069 | 1/20 | 0.50 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.48 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.47 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.47 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.47 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.47 |
| ▸ | BRAF | P15056 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14905514 | 0.82 | FGFR3 (0.52) | PDGFRBPDGFRAMEN1NPC1RAB9A | |
| SCHEMBL3084895 | 0.78 | PDGFRB (0.53) | PDGFRBPDGFRAMEN1KMT2ACYP11B2 | |
| SCHEMBL3095616 | 0.75 | PIK3CD (0.59) | PDGFRBPDGFRAPIK3CAPIK3CBPIK3CG | |
| SCHEMBL14475830 | 0.74 | ABCG2 (0.83) | MEN1KMT2AABCG2ABCB1PIK3CA | |
| SCHEMBL792083 | 0.74 | CYP11B2 (0.73) | MEN1NPC1RAB9ACYP11B2CYP17A1 | |
| SCHEMBL29566706 | 0.74 | CYP11B2 (0.73) | MEN1NPC1RAB9ACYP11B2CYP17A1 | |
| SCHEMBL3906854 | 0.74 | PDGFRB (0.61) | PDGFRBPDGFRAMEN1NPC1RAB9A | |
| SCHEMBL7474612 | 0.74 | PIK3CG (0.76) | PDGFRBPDGFRAMEN1NPC1RAB9A | |
| SCHEMBL16421990 | 0.73 | FGFR3 (0.65) | PDGFRBPDGFRAMEN1NPC1RAB9A | |
| SCHEMBL14906698 | 0.72 | PDGFRB (0.57) | PDGFRBPDGFRAMEN1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234386-A1 | QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2010-09-16 | — | — | US | disclosed |
| US-20100234386-A1 | QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2010-09-16 | — | — | US | disclosed |
| US-20100234386-A1 | QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2010-09-16 | — | — | US | disclosed |
| US-7592342-B2 | Quinoxaline derivatives as PI3 kinase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| US-7592342-B2 | Quinoxaline derivatives as PI3 kinase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| US-7592342-B2 | Quinoxaline derivatives as PI3 kinase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| US-20080293706-A1 | QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC | 2008-11-27 | — | — | US | disclosed |
| US-20080293706-A1 | QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC | 2008-11-27 | — | — | US | disclosed |
| US-20080293706-A1 | QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC | 2008-11-27 | — | — | US | disclosed |
| WO-2008141065-A1 | QUINOXALINE DERIVATIVES AS P13 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293706-A1 | QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS | PIP5K1A, PIK3CB, PIK3CG | PDGFRB 85/4885PDGFRA 159/4885MEN1 1927/4885 |
| US-20100234386-A1 | QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS | PIP5K1A, PIK3CB, PIK3CG | PDGFRB 85/4885PDGFRA 159/4885MEN1 1927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.